DBV DBV Technologies SA

Information regarding the total number of voting rights and total number of shares of the Company as of March 31, 2024

Information regarding the total number of voting rights and total number of shares of the Company as of March 31, 2024

                                                                                                                                                                                                                                                                                                                 

Information regarding the total number of voting rights and

total number of shares of the Company as of March 31, 2024

(Article 223-16 of the General Regulations of the Autorité des Marchés Financiers)

Market : NYSE Euronext Paris

ISIN Code: FR 0010417345

 



Date



 		Total number of shares Total number of voting rights
03/31/2024



 		96,434,369



 		 



Total gross of voting rights: 96,434,369



 
 



Total net* of voting rights: 96,171,725



 

* Net total = total number of voting rights attached to shares – shares without voting rights

Attachment



EN
04/04/2024

Underlying

DBVDBV Technologies SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on DBV Technologies SA

 PRESS RELEASE
Free
DBV DBV Technologie...

DBV Technologies annonce son intention de modifier le ratio d'ADS

DBV Technologies annonce son intention de modifier le ratio d'ADS Châtillon, France, le 17 mai 2024 DBV Technologies annonce son intention de modifier le ratio d'ADS DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT—CUSIP: 23306J101), une société biopharmaceutique au stade clinique spécialisée dans les options de traitement des allergies alimentaires et d'autres conditions immunologiques dont les besoins médicaux ne sont pas satisfaits (« la Société »), a annoncé aujourd'hui son intention de modifier le ratio de ses American Depositary Shares ("ADS") par ra...

May 17, 2024 1 EN
 PRESS RELEASE
Free
DBV DBV Technologie...

DBV Technologies Announces Plan to Implement ADS Ratio Change

DBV Technologies Announces Plan to Implement ADS Ratio Change Châtillon, France, May 17, 2024 DBV Technologies Announces Plan to Implement ADS Ratio Change DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT—CUSIP: 23306J101), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today announced plans to change the ratio of its American Depositary Shares (“ADSs”) to its ordinary shares (the “ADS Ratio”), nominal value €0.10 (ten cents) per share, from the...

May 17, 2024 1 EN
 PRESS RELEASE
Free
DBV DBV Technologie...

DBV Technologies Announces Results of its 2024 Combined General Meetin...

DBV Technologies Announces Results of its 2024 Combined General Meeting Châtillon, France, May 16, 2024 DBV Technologies Announces Results of its 2024 Combined General Meeting Shareholders approved all proposed resolutions DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT) (the “Company”), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, held its Combined General Meeting (the “General Meeting”). The General Meeting was chaired by Michel de Rosen,...

May 16, 2024 1 EN
 PRESS RELEASE
Free
DBV DBV Technologie...

DBV Technologies annonce les résultats de son Assemblée Générale Mixte...

DBV Technologies annonce les résultats de son Assemblée Générale Mixte 2024 Châtillon, France, le 16 mai 2024 DBV Technologies annonce les résultats de son Assemblée Générale Mixte 2024 Toutes les résolutions proposées à l’Assemblée Générale ont été adoptées DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq Stock Market : DBVT), (la « Société »), une entreprise biopharmaceutique de stade clinique spécialisée dans le développement d’options de traitement des allergies alimentaires et autres affections immunologiques ayant d’importants besoins médicaux non satisfaits, a tenu...

May 16, 2024 1 EN
 PRESS RELEASE
Free
DBV DBV Technologie...

DBV Technologies to Participate in Upcoming Investor Conferences

DBV Technologies to Participate in Upcoming Investor Conferences Montrouge, France, May 9, 2024 DBV Technologies to Participate in Upcoming Investor Conferences DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today announced Daniel Tassé, Chief Executive Officer, will deliver a company presentation at two investor conferences in May. Citizens JMP Life Scie...

May 9, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch